IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

Compare

634 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDYA Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

IDEAYA

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDYA Stock 12 Month Forecast

Average Price Target

$49.86

▲(36.87% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $49.86 with a high forecast of $79.00 and a low forecast of $30.00. The average price target represents a 36.87% change from the last price of $36.43.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","80":"$80","29.75":"$29.8","46.5":"$46.5","63.25":"$63.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,29.75,46.5,63.25,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,37.987692307692306,41.40538461538462,44.823076923076925,48.24076923076923,51.65846153846154,55.076153846153844,58.49384615384616,61.91153846153846,65.32923076923078,68.74692307692308,72.16461538461539,75.5823076923077,{"y":79,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,35.746153846153845,36.92230769230769,38.098461538461535,39.27461538461539,40.45076923076923,41.62692307692308,42.80307692307692,43.97923076923077,45.15538461538462,46.33153846153846,47.50769230769231,48.683846153846154,{"y":49.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,34.21846153846154,33.86692307692308,33.51538461538462,33.16384615384615,32.81230769230769,32.46076923076923,32.10923076923077,31.75769230769231,31.406153846153845,31.054615384615385,30.70307692307692,30.35153846153846,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.86,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.31,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$79.00

Average Price Target$49.86

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

$59→$60

Buy

64.70%

Upside

Reiterated

01/06/26

Truist Financial Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)

Michael Yee

UBS

$50

Buy

37.25%

Upside

Initiated

01/06/26

Ideaya Biosciences assumed with a Buy at UBSIdeaya Biosciences assumed with a Buy at UBS

Charles Zhu

LifeSci Capital

$62

Buy

70.19%

Upside

Reiterated

01/04/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK) and IDEAYA Biosciences (NASDAQ: IDYA)

Yigal Nochomovitz

Citi

$64

Buy

75.68%

Upside

Initiated

12/12/25

Promising Outlook for IDEAYA Biosciences: Buy Rating Backed by Positive Trial Expectations

Paul Jeng

Guggenheim

$50

Buy

37.25%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and PACS Group Inc (NYSE: PACS)

Graig Suvannavejh

Mizuho Securities

$46

Buy

26.27%

Upside

Reiterated

12/08/25

Mizuho Securities Remains a Buy on IDEAYA Biosciences (IDYA)

Leonid Timashev

RBC Capital

$41

Buy

12.54%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/04/25

IDEAYA Biosciences: Promising Clinical Developments and Strategic Potential Drive Buy Rating

Matthew Biegler

Oppenheimer

$36

Buy

-1.18%

Downside

Reiterated

11/04/25

Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Peter Lawson

Barclays

$40

Buy

9.80%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Gets a Buy from Barclays

Justin Zelin

BTIG

$62

Buy

70.19%

Upside

Reiterated

11/04/25

IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

Anupam Rama

J.P. Morgan

$74→$79

Buy

116.85%

Upside

Reiterated

10/23/25

Ideaya Biosciences price target raised to $79 from $74 at JPMorganIdeaya Biosciences price target raised to $79 from $74 at JPMorgan

Andrew Berens

Leerink Partners

$30→$33

Hold

-9.42%

Downside

Reiterated

10/21/25

Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)

Corinne Johnson

Goldman Sachs

$27→$30

Hold

-17.65%

Downside

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)

Silvan Tuerkcan

Citizens JMP

$45

Buy

23.52%

Upside

Reiterated

10/13/25

Citizens JMP Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

$59→$60

Buy

64.70%

Upside

Reiterated

01/06/26

Truist Financial Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)

Michael Yee

UBS

$50

Buy

37.25%

Upside

Initiated

01/06/26

Ideaya Biosciences assumed with a Buy at UBSIdeaya Biosciences assumed with a Buy at UBS

Charles Zhu

LifeSci Capital

$62

Buy

70.19%

Upside

Reiterated

01/04/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK) and IDEAYA Biosciences (NASDAQ: IDYA)

Yigal Nochomovitz

Citi

$64

Buy

75.68%

Upside

Initiated

12/12/25

Promising Outlook for IDEAYA Biosciences: Buy Rating Backed by Positive Trial Expectations

Paul Jeng

Guggenheim

$50

Buy

37.25%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and PACS Group Inc (NYSE: PACS)

Graig Suvannavejh

Mizuho Securities

$46

Buy

26.27%

Upside

Reiterated

12/08/25

Mizuho Securities Remains a Buy on IDEAYA Biosciences (IDYA)

Leonid Timashev

RBC Capital

$41

Buy

12.54%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/04/25

IDEAYA Biosciences: Promising Clinical Developments and Strategic Potential Drive Buy Rating

Matthew Biegler

Oppenheimer

$36

Buy

-1.18%

Downside

Reiterated

11/04/25

Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Peter Lawson

Barclays

$40

Buy

9.80%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Gets a Buy from Barclays

Justin Zelin

BTIG

$62

Buy

70.19%

Upside

Reiterated

11/04/25

IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

Anupam Rama

J.P. Morgan

$74→$79

Buy

116.85%

Upside

Reiterated

10/23/25

Ideaya Biosciences price target raised to $79 from $74 at JPMorganIdeaya Biosciences price target raised to $79 from $74 at JPMorgan

Andrew Berens

Leerink Partners

$30→$33

Hold

-9.42%

Downside

Reiterated

10/21/25

Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)

Corinne Johnson

Goldman Sachs

$27→$30

Hold

-17.65%

Downside

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)

Silvan Tuerkcan

Citizens JMP

$45

Buy

23.52%

Upside

Reiterated

10/13/25

Citizens JMP Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+5.72%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +5.72% per trade.

3 Months

xxx

Success Rate

17/24 ratings generated profit

Average Return

+12.08%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.83% of your transactions generating a profit, with an average return of +12.08% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

20/24 ratings generated profit

Average Return

+51.61%

reiterated a buy rating 7 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +51.61% per trade.

2 Years

xxx

Success Rate

20/24 ratings generated profit

Average Return

+54.51%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +54.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDYA Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDYA has received 18 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 49.86.

Each month's total comprises the sum of three months' worth of ratings.

IDYA Financial Forecast

IDYA Earnings Forecast

Next quarter’s earnings estimate for IDYA is -$0.95 with a range of -$1.19 to -$0.70. The previous quarter’s EPS was $1.47. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Sales Forecast

Next quarter’s sales forecast for IDYA is $6.12M with a range of -$1.60M to $22.20M. The previous quarter’s sales results were $207.83M. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Stock Forecast FAQ

What is IDYA’s average 12-month price target, according to analysts?

Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 49.86.

What is IDYA’s upside potential, based on the analysts’ average price target?

IDEAYA Biosciences has 36.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IDYA a Buy, Sell or Hold?

IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is IDEAYA Biosciences’s price target?

The average price target for IDEAYA Biosciences is 49.86. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $30.00. The average price target represents 36.87% Increase from the current price of $36.43.

What do analysts say about IDEAYA Biosciences?

IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of IDYA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

IDYA Analyst Ratings

IDYA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering IDEAYA Biosciences

IDYA Analyst Recommendation Trends

IDYA Financial Forecast

IDYA Earnings Forecast

IDYA Sales Forecast

IDYA Stock Forecast FAQ

Detailed List of Analyst Forecasts